Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
106
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Definium Therapeutics Inc. market cap is $4.04B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Definium Therapeutics Inc. 52 week high is $49.70 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Definium Therapeutics Inc. 52 week low is $10.46 as of November 20, 2026.
Definium Therapeutics Inc. stock price today is $28.34.
Definium Therapeutics Inc. stock price yesterday was $29.48.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Definium Therapeutics Inc.'s P/E ratio is -9.73.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Definium Therapeutics Inc. P/B ratio is 4.1687.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Definium Therapeutics Inc. 50-day moving average is $35.39.